Extension_BioXcellence_Fremont

Boehringer Ingelheim achieves next expansion milestone in biologics production in the USCulmination of a €200 million investment in CaliforniaWorldwide capacity for manufacturing biopharmaceutical medicines now exceeds 290,000 litersGlobal manufacturing network for products in Boehringer Ingelheim ’s own research pipeline and for contract manufacturing

Source: Boehringer Ingelheim Corporate News - October 30, 2018 Category: Research Source Type: news